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Wood-Smoke Exposure
as a Response and
Survival Predictor in
Erlotinib-Treated
Nonsmall Cell Lung
Cancer Patients
To the Editor:
In relation to the letter to the edi-
tor written by Cardona et al.1 published
in the Journal of Thoracic Oncology on
January 2009 referring to our article
entitled “Wood-Smoke Exposure as a Re-
sponse and Survival Predictor in Erlotinib-
treated Nonsmall Cell Lung Cancer Pa-
tients: An Open Label Phase II Study,”2 in
which Cardona et al. concluded that the
findings that we previously published are
not supported by them, some statements
should be made: their study is based ex-
clusively on an experience-established
treatment of 156 adenocarcinoma patients,
not a prospective clinical trial. Of these
156 patients, only 23% (36 patients) re-
ceived erlotinib. It does not mention at-
tachment to treatment of the patients,
which might be an issue, considering
that those exposed to wood-smoke gen-
erally belong to lower socioeconomic
status than those who have no history
of exposure and depend on study in-
clusion to receive treatment.
Moreover, of the erlotinib-treated
patients, just nine of them had wood-
smoke exposure (WSE) history and seven
of them also had smoking history for an
average of 14 years. Our hypothesis about
nonsmall cell lung cancer patients with
WSE and their response to tyrosine kinase
inhibitors treatment suggests that the path-
ways involved in carcinogenesis in WSE
patients and smokers are different, reason
for which nonsmall cell lung cancer de-
velopment could be attributed solely to
WSE in two patients of their series. There-
fore, the sample is not representative.
Furthermore, there is a mistake in
their statistical analysis. Cardona et al.
states a 5% response rate to erlotinib in
WSE patients with a sample size of
merely nine patients, which corresponds
to 0.45 patients, assuming that only one
patient had shown response it would be
equal to 11.11% of patients.
Also, their reported response rate
in non-WSE patients, including smokers
and nonsmokers, is of 47%, which is
strikingly high and is different from data
that have been previously reported by
Shepherd et al.3 in a phase III study that
included 731 patients with a response
rate of 8.9% and, exclusively, 29% of
patients in the adenocarcinoma subtype.
Their rate of response is not comparable
either with the TRUST4 study that in-
vestigated the extended use of erlotinib
in 5448 patients with a reported response
rate of 12%. However, this information is
consistent with our finding of a response
rate of 12.3% in non-WSE patients. We
would welcome the authors’ clarification
of their numbers in case we have misin-
terpreted them.
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Esophageal Ultrasound-
Controlled Fine Needle
Aspiration for Staging
of Mediastinal Lymph
Nodes in Patients with
Resectable Lung
Cancer: Do We Always
See the Reality?
To the Editor:
Accurate mediastinal lymph node
staging is pivotal in the staging and
treatment of non-small cell lung can-
cer.1,2 Echoendoscopic needle aspira-
tion is a minimally invasive staging
technique with a good sensitivity and
100% specificity. However, physicians
performing and relying on esophageal
ultrasound-controlled fine needle aspi-
ration (EUS-FNA) should be aware of
potential hurdles related to this tech-
nique such as
Parenchymal lung lesions adjacent to
the esophagus can be sampled and
care must be taken in their radio-
graphic and cytologic interpretation.
Lymphocytes in an needle aspiration
sample do not always indicate a lymph
node was sampled.
EUS-FNA may allow sampling of hilar
lymph nodes.
As such, EUS-FNA may result in clini-
cal overstaging (N2 instead of N0 or N1)
having an important impact on patient
treatment and prognosis. Here, we
present two cases illustrating potential
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